MOUNTAIN VIEW, CA – January 17, 2025 - Frontiers in Pharmacology has published the results of the preclinical study on the potential of elocalcitol to prevent diet-induced obesity and metabolic syndrome: Article

Adge Pharmaceuticals Inc. is evaluating elocalcitol, a.k.a. RO269228, a clinical stage small molecule originally developed by Roche, for the treatment of obesity and potentially other indications with unmet medical needs.

Obesity is a chronic health condition that leads to metabolic syndrome and raises the risk for heart disease and many other health problems, including type 2 diabetes and cancer. It is manifested in increase in size and amount of fat cells in the body. Nearly 80% of the US population is projected to be overweight or obese by 2050. Obesity is also known to exacerbate the age-related decline.

Metabolic syndrome is defined by the presence of a cluster of cardiovascular risk factors which include excess abdominal fat, hypertension, glucose intolerance, insulin resistance, high triglycerides, high LDL and low HDL.

Adge Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of best-in-class therapies for the management of obesity and metabolic syndrome.

For more information, please visit www.adgepharm.com.